Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.40B | 1.05B | 1.23B | 1.27B | 1.22B |
Gross Profit | 753.36M | 551.31M | 770.75M | 806.28M | 781.07M |
EBITDA | 260.87M | 193.05M | 229.06M | 2.13B | 279.43M |
Net Income | 93.10M | 16.70M | 51.28M | 1.99B | 78.53M |
Balance Sheet | |||||
Total Assets | 2.62B | 2.89B | 2.78B | 3.64B | 3.25B |
Cash, Cash Equivalents and Short-Term Investments | 216.84M | 171.00M | 189.30M | 277.53M | 414.54M |
Total Debt | 227.30M | 204.14M | 163.49M | 267.14M | 156.71M |
Total Liabilities | 1.07B | 930.07M | 939.50M | 1.25B | 1.14B |
Stockholders Equity | 1.65B | 2.04B | 1.92B | 2.46B | 2.15B |
Cash Flow | |||||
Free Cash Flow | 34.45M | -45.89M | 69.81M | -160.04M | -139.23M |
Operating Cash Flow | 242.01M | 110.08M | 283.63M | 210.68M | 218.91M |
Investing Cash Flow | -192.36M | -145.22M | -256.05M | -370.28M | -523.74M |
Financing Cash Flow | -1.96M | 13.44M | -128.60M | 60.97M | -9.80M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | HK$6.43B | 7.06 | 11.61% | 6.07% | -18.09% | -15.08% | |
73 Outperform | HK$1.97B | 3.22 | 18.33% | 5.78% | -9.95% | 67.56% | |
70 Outperform | HK$10.52B | 11.60 | 8.89% | 3.81% | 4.91% | -11.80% | |
66 Neutral | HK$1.12B | 12.08 | 5.04% | 2.39% | 32.95% | 456.69% | |
60 Neutral | HK$19.22B | 4.48 | -1.43% | 3.30% | 11.19% | -15.58% | |
49 Neutral | $13.90B | ― | -4.93% | 1.41% | -0.11% | -290.77% |
Lee’s Pharmaceutical Holdings Limited has announced a board meeting scheduled for August 26, 2025, to discuss and approve the unaudited interim results for the first half of 2025, and to consider the recommendation of an interim dividend. This meeting is significant as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and stakeholder interests.
Lee’s Pharmaceutical Holdings Limited announced the approval of Socazolimab, an oncology drug developed by its subsidiary China Oncology Focus Limited, for marketing in combination with chemotherapy for the first-line treatment of extensive-stage small-cell lung cancer in Mainland China. The approval by the National Medical Products Administration is based on a successful Phase III clinical trial that demonstrated significant overall survival benefits without increasing safety risks. This development strengthens Lee’s Pharm’s position in the oncology market and underscores its commitment to advancing cancer treatment options.
Lee’s Pharmaceutical Holdings Limited held its Annual General Meeting on May 22, 2025, where all proposed resolutions were passed. Key resolutions included the approval of audited financial statements, declaration of a final dividend, re-election of directors, and granting of mandates for share repurchase and issuance. The successful passing of these resolutions indicates strong shareholder support and positions the company for continued operational stability and strategic growth.